Quarterly ResultAug 13, 2026, 08:32 AM
Cingulate Q2 Net Loss $5.9M; CTx-1301 NDA Resubmission Progress
AI Summary
Cingulate Inc. reported a net loss of $5.9 million for Q2 2026, an increase from $5.0 million in Q2 2025, primarily due to higher selling, general and administrative expenses for commercial readiness. The company provided updates on its lead ADHD asset, CTx-1301, including ongoing progress for NDA resubmission to the FDA and the issuance of a new U.S. patent extending protection through December 2042. Cash and cash equivalents significantly increased to $28.4 million, expected to fund operations into mid-2027, supporting continued commercialization preparations and regulatory efforts.
Key Highlights
- Q2 2026 Net Loss: $5.9 million, compared to $5.0 million in Q2 2025.
- Q2 2026 R&D expenses: $1.5 million, a 44.9% decrease YoY.
- Q2 2026 SG&A expenses: $3.9 million, a 101.5% increase YoY.
- Cash and cash equivalents: $28.4 million as of June 30, 2026.
- Working capital: $21.6 million as of June 30, 2026.
- New U.S. Patent No. 12,653,791 for CTx-1301 issued, protecting through December 2042.
- Progress on CMC work for CTx-1301 NDA resubmission to FDA.
- Signed exclusive distribution agreement with Prasco, LLC for CTx-1301.
Price Impact
More from CING